Init. Robam w/Buy & D/G Guoxuan to Hold;Manufacturing PMI; Macau, Healthcare US Biotechnology: BLUE & CELG: bb2121 Shows Highly Impressive Early Clinical Profile - ALERT Trump Impact TBD, but Should Not Derail Medium-Term Growth Potential Led by IT November fell slightly short of expectations Bermuda Trip Takeaways: Price Declines Could Slow and M&A Could Persist Capital flows: China Vs the US Cement Prices Flat Last Week; Xinjiang Took the Lead in Removing Grade 32.5 Cement Leader benefits from industry volatility Draft subsidies imply more margin pressure; downgrading to Hold Growing the premium kitchen appliance brand; initiating with Buy